Author Interviews, Infections, NEJM, Pediatrics, Vaccine Studies / 02.02.2023

MedicalResearch.com Interview with: Manuel García Cenoz MD,  PhDInstituto de Salud Pública de Navarra - IdiSNA, Pamplona, SpainCIBER Epidemiología y Salud Pública, Madrid MedicalResearch.com: What is the background for this study? Response: Neisseria meningitidis is a major cause of severe disease in infants and children. After the introduction of serogroup C vaccines, serogroup B meningococcus has become the main cause of invasive meningococcal disease in Europe. The multicomponent protein-based meningococcal B vaccine (4CMenB, Bexsero, GSK) was licensed in the European Union in 2013. Its authorization was based on immunogenicity studies. Although some countries have introduced the 4CMenB vaccine into the publicly-funded infant immunization programs, the low incidence of the disease has limited the conduct of post-commercialization studies of effectiveness.Meningococcal B vaccine began to be used in Spain in children in 2014, recommended by the Spanish Association of Pediatrics, and paid by their families as it was not publicly-funded. We have conducted a nationwide study including all confirmed cases of invasive meningococcal disease in Spain between October 2015 and September 2019 in children aged two months to five years. (more…)
Author Interviews, Genetic Research, Infections, Neurological Disorders / 14.12.2022

MedicalResearch.com Interview with: Dr. Eli Hatchwell, MA MB BChir (Cantab) DPhil (Oxon) BA (OU) Chief Scientific Officer Population Bio UK, Inc. Begbroke Science Park Begbroke Hill Begbroke, Oxfordshire United Kingdom MedicalResearch.com: What is the background for this study? Response: Progressive Multifocal Leukoencephalopathy (PML) is a devastating condition that is associated with a number of clinical situations, including treatment with a variety of drugs. Of these, the best known is natalizumab (Tysabri), which is a very successful drug in the treatment of MS (multiple sclerosis). Only a small proportion of patients treated with natalizumab develop PML and this has always been a mystery. The study was based on a hypothesis that some individuals have an underlying susceptibility to developing PML, based on the presence of variants in genes that are important in the immune system. The study identified several of these variants. (more…)
Alzheimer's - Dementia, Author Interviews, Infections, Parkinson's / 22.09.2022

MedicalResearch.com Interview with: Jiangwei Sun PhD Postdoctoral researcher in Prof. Jonas Ludvigsson's group Department of Medical Epidemiology and Biostatistics Karolinska Institutet MedicalResearch.com: What is the background for this study? Response: A potential infectious etiology has been hypothesized for neurodegenerative diseases, as findings in animal studies have demonstrated that infectious processes might impact pathogenesis, phenotype, and progression of neurodegenerative disease. The extrapolation of such findings to a human context is however not straightforward. previous studies have mostly examined the role of specific pathogens on a specific neurodegenerative disease, e.g., herpesvirus for Alzheimer’s disease, and influenza, hepatitis C virus, and Helicobacter pylori for PD, with inconclusive results. Although several studies have also assessed associations between infectious diseases and risk of dementia and AD, influence of potential surveillance bias (greater-than-expected surveillance of disease after infections) and reverse causation (due to for example diagnostic delay of neurodegenerative diseases) on the associations was not always fully addressed. Therefore, whether infection is indeed a risk factor rather a comorbidity or secondary event of neurodegenerative disease remains unknown. In contrast to Alzheimer’s disease, and Parkinson’s disease, the potential link between infection and ALS has been less explored. (more…)
Author Interviews, BMJ, Infections / 01.08.2022

MedicalResearch.com Interview with: Dr Aatish Patel Guy’s and St Thomas’ NHS Foundation Trust MedicalResearch.com:  What is the background for this case series?    Response: This case series was based on observations we made whilst treating patients with monkeypox, and the request of many of these patients for better public health messaging surrounding signs and symptoms to be aware of. (more…)
Author Interviews, Dermatology, Infections / 15.07.2022

MedicalResearch.com Interview with: Dr Dilip Kachhawa, MD Department of Skin & Venereal Disease Dr Sampurnanand Medical College Jodhpur, Rajasthan, India MedicalResearch.com:  What are the main findings? Response: Molluscum Contagiosum (MC) is an infection caused by molluscipoxvirus. It is difficult to study since the virus only survives in human skin, and therefore there isn’t an animal or cell model to study potential treatments. Molluscum lesions appear as raised, domed shaped skin-colored lesions and can occur anywhere on the body but are most common on the face, neck, arms, legs, and abdomen. Sometimes there are few lesions, but clusters of several lesions can appear. Children are the most likely to get molluscum, and the virus is highly contagious, transmitted by direct contact with infected skin or contaminated objects, like towels, linens and toys. Scratching can cause autoinoculation which is when a person reinfects themself. MC is very common, impacting an estimated 6 million adults and mostly children in the US each year. In 2010, there was an estimated 122 million cases worldwide. It occurs primarily in humid and warm climates, and transmission via swimming pools and bathtubs may be possible. Therefore, molluscum is often called “water warts.” Many physicians may take a “watch and wait” approach since the virus may clear on its own. However, it can take months to up to 5 years for some to experience complete clearance, In the meantime, the person is still highly contagious and may spread the virus to others, particularly children. Lesions can be bothersome, causing itching and sometimes a secondary infection. There is also a psychosocial component. In a recent study, 1 in 10 children with molluscum experienced a major quality of life issue. Berdazimer Gel, 10.3% is a potential first-in-class topical controlled-nitric oxide releasing medication containing Berdazimer (sodium), a new chemical entity, and the active ingredient in berdazimer gel 10.3%. The mechanism of action of berdazimer in the treatment of molluscum is unknown, but in vitro lab studies show that the nitric oxide, released when berdazimer is combined with a hydrogel, may impede viral replication and perhaps help body’s natural immune response against molluscum. (more…)
Author Interviews, Infections, NIH / 30.06.2022

MedicalResearch.com Interview with: Nihal Altan-Bonnet, Ph.D. Chief of the Laboratory of Host-Pathogen Dynamics NHLBI  MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: Enteric viruses such as norovirus, rotavirus and astrovirus are responsible for nearly 1.5 billion global infections per year resulting in gastrointestinal illnesses and sometimes leading to death in the very young, in the elderly and in the immunocompromised. These viruses have been thought to traditionally infect and replicate only in the intestines, then shed into feces and transmit to others via the oral-fecal route (e.g. through ingestion of fecal contaminated food items). Our findings reported in Nature, using animal models of norovirus, rotavirus and astrovirus infection, challenge this traditional view and reveal that these viruses can also replicate robustly in salivary glands, be shed into saliva in large quantities and transmit through saliva to other animals. In particular we also show infected infants can transmit these viruses to their mothers mammary glands via suckling and this leads to both an infection in their mothers mammary glands but also a rapid immune response by the mother resulting in a surge in her milk antibodies. These milk antibodies may play a role in fighting the infection in their infants .  (more…)
Author Interviews, Critical Care - Intensive Care - ICUs, Infections / 29.03.2022

MedicalResearch.com Interview with: Michael J. Mahan Ph.D. Professor Dept of Molecular, Cellular, and Developmental Biology University of California Santa Barbara, CA MedicalResearch.com:  What is the background for this study?  What are the main findings?  Response:  Sepsis is the number one cause of death in US hospitals- but few molecular diagnostics and therapies exist for this condition. In the clinic, sepsis is diagnosed by a symptom-based approach that may include kidney or liver failure, blood clotting or bleeding — which is often well after permanent organ damage. Thus, molecular diagnostics that detect infection at early stages of disease to minimize host injury are sorely needed. (more…)
Author Interviews, Brigham & Women's - Harvard, Infections, Multiple Sclerosis, Science / 15.01.2022

MedicalResearch.com Interview with: Kassandra L. Munger Sc.D. Senior Research Scientist Alberto Ascherio MD Dr.P.H. Professor of Epidemiology and Nutrition Harvard T.H. Chan School of Public Health MedicalResearch.com: What is the background for this study? Response: An infectious cause of MS has been hypothesized for decades. Research over the past 20 years conducted by our group and others has strongly suggested a role for EBV infection including that EBV-negative individuals have a near zero risk of developing MS, having a history of infectious mononucleosis (caused by EBV infection) increases the risk of MS 2-fold, and healthy individuals have higher risks of MS with higher antibody levels against EBV antigens.  Ideally, to prove causality a randomized clinical controlled trial would be conducted; however, this not a feasible approach in this case. Given that nearly 95% of the adult population is infected with EBV and MS is a rare disease, we utilized the Department of Defense Serum Repository which stores over 60 million serum samples from over 10 million US Military active duty personnel. From this large resource, we were able to identify a cohort who were EBV negative when they joined the military and we followed them for whether they had a primary infection with EBV and then for who developed MS. (more…)
Author Interviews, CDC, Infections / 07.12.2021

MedicalResearch.com Interview with: Michael Craig MPP Director, Antibiotic Resistance Coordination and Strategy CDC  MedicalResearch.com: What is the mission of the Global Action in Healthcare Network (GAIHN)? How will it work to coordinate detection and response efforts across multiple countries and cultures? 
  • Health care can often be an epicenter of infectious disease outbreaks that can spread within a facility, between facilities, and beyond the facility into the community. CDC’s Global Action in Healthcare Network (GAIHN) consists of countries, healthcare facilities, and public health partners working together to prevent, detect, and respond to infectious disease threats in the healthcare setting. GAIHN will target health care threats like antimicrobial-resistant infections, healthcare-associated infections (HAIs), and COVID-19 through infection prevention and control.
  • Close coordination across experts at CDC, and strong relationships and communications with our funded partners, international colleagues, ministries of health and country leadership, will make GAIHN successful and ensure collaboration, minimize duplication, and maximize advancements across countries and cultures.
  • Find more information about the 2021 GAIHN projects: https://www.cdc.gov/infectioncontrol/global/GAIHN.html 
(more…)
Author Interviews, Infections, JAMA, Multiple Sclerosis, Neurological Disorders / 27.10.2021

MedicalResearch.com Interview with: Prof. Scott Montgomery Professor of medical science (clinical epidemiology) Örebro University, Sweden Director of Clinical Epidemiology and Biostatistics Örebro University Hospital, Sweden MedicalResearch.com: What is the background for this study? Response: Infections have been linked with increased risk of subsequent multiple sclerosis (MS), but it has been suggested this may be because the genetic or other family characteristics of people who go on to develop MS have a more severe response to infections: the infections would be more likely to be recorded in those who would subsequently develop MS, rather than being risk factors for the disease. To address this issue, we performed a large study of 2,492,980 people living in Sweden, and 5,867 of them had a diagnosis of MS after age 20 years. We identified who had a hospital diagnosis of infectious mononucleosis (caused by Epstein-Barr virus, EBV infection, and also known as glandular fever or the kissing disease). The new study was different from other studies of infection and MS risk, as it compared siblings in the same families. Siblings share much of their genetic make-up and have similar family lives. If glandular fever is associated with later MS when siblings are compared, then it is unlikely that the association is caused by genetics or other family characteristics that make infections worse in people more likely to develop future MS. (more…)
Author Interviews, HIV, Infections, Vanderbilt / 02.10.2021

MedicalResearch.com Interview with: Rachael Pellegrino, MD Vanderbilt University Medical Center MedicalResearch.com: What is the background for this study? Response: We know that HIV care and outcomes have dramatically improved over the last 20 years, but disparities still exist at each step of the HIV care continuum, which can ultimately lead to differences in mortality rates. In addition to assessing trends and disparities in mortality, we wanted to look at differences in premature mortality, which has not been widely studied in the HIV population in the US. This concept serves to emphasize and quantify the time lost by death at an early age as an important measurement of the impact of diseases and can expose disparities that are not apparent in the mortality rates alone. (more…)
Author Interviews, Critical Care - Intensive Care - ICUs, Infections / 02.10.2021

MedicalResearch.com Interview with: Chanu Rhee, MD, MPH Harvard Medical School and Harvard Pilgrim Health Institute Boston, MA MedicalResearch.com: What is the background for this study? Response: Sepsis is a leading cause of death, disability, and healthcare costs.  This has triggered regulators and hospitals to invest heavily in improving sepsis recognition and care.  Most notably, the Centers for Medicare & Medicaid Services (CMS) implemented the Severe Sepsis/Septic Shock Early Management Bundle (SEP-1) by the in October 2015.  SEP-1 requires hospitals to report compliance with a 3 and 6 hour sepsis care bundle, which includes initial and repeat lactate measurements, blood culture orders, broad-spectrum antibiotic, specific quantities of fluid boluses for hypotension, vasopressors for persistent hypotension, and documentation of a repeat volume and perfusion assessment for patients with septic shock. While SEP-1 has helped raise awareness of sepsis and catalyzed sepsis quality improvement initiatives around the country, concerns have been raised about its potential unintended consequences -- particularly around increasing unnecessary broad spectrum antibiotic use -- and the strength of evidence supporting the measure.  In this study, we used detailed clinical data from a diverse cohort of hospitals to assess whether SEP-1 implementation was associated with changes in key processes of care and mortality in patients with suspected sepsis.  (more…)
Author Interviews, Infections / 11.07.2021

MedicalResearch.com Interview with: Juliana Menezes MSc “I am a PhD student at the Faculty of Veterinary Medicine of the University of Lisbon. I do my research at the Centre for Interdisciplinary Research in Animal Health under the Supervision of Professor Constança Pomba, the head of the Antibiotic Resistance Lab. The Idea for this work came from my supervisor, that has been working in the field of antibiotic resistance for a while and was leading a research project, the Pet-Risk consortium (http://petrisk.fmv.ulisboa.pt/) which main goal was to evaluate sharing of resistant bacteria between animal and humans (namely ESBL). Following this idea, we thought that would be important to evaluate colistin resistance in animals.” MedicalResearch.com: What is the background for this study? Response: With the global spread of multi-drug carbapenem resistant Gram-negative bacteria, colistin is a last-resort antimicrobial to treat ICU patients in hospitals. Thus, WHO has classified Colistin as a Highest Priority Critically Important Antimicrobial for human medicine, therefore, resistance represents a serious concern among physicians and scientists.  Increasing trends and prevalence of colistin resistance have been observed worldwide, and the studies are mainly focused on food-producing animals or hospitalized humans, suggesting an exchange of pathogenic bacteria and/or mobile genetic elements between different reservoirs. The rational for this study is the importance to evaluate colistin resistance in companion animals as they are living in direct contact with humans in the community. (more…)
Author Interviews, Infections / 22.06.2021

MedicalResearch.com Interview with: Dr. Rafael Kroon Campos PhD Department of Microbiology and Immunology University of Texas Medical Branch Galveston, TX MedicalResearch.com: What is the background for this study? What are the main findings? Response: The COVID-19 pandemic is affecting millions of people. COVID-19 is a disease that primarily affects the lungs, but it also affects other organs and tissues, including heart and olfactory receptors. There is a growing body of evidence showing that COVID-19 can affect reproductive health by reducing androgen hormones, sperm counts and causing pain and discomfort in the testes. The virus that causes this disease is named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is unknown whether these symptoms are caused by direct virus testes infection or a byproduct of the immune system fighting the virus. (more…)
Author Interviews, Infections, Respiratory / 25.03.2021

MedicalResearch.com Interview with: Pranay Sinha, MD Section of Infectious Diseases Boston University School of Medicine MedicalResearch.com: What is the background for this study? Response: We hypothesized that mitigation measures such as physical distancing and mask wearing instituted in Boston would reduce transmission of common respiratory viruses such as influenza, Rhinovirus, and Parainfluenzavirus. We compared the rate of detection of such viruses at Boston Medical Center on comprehensive respiratory panels in the ambulatory, emergency room, and hospital settings in 2020 to rates in the previous five years. (more…)
Author Interviews, COVID -19 Coronavirus, Infections, UCSD / 13.03.2021

MedicalResearch.com Interview with: Abhishek Saha, PhD Assistant Professor Department of Mechanical and Aerospace Engineering University of California San Diego MedicalResearch.com: What is the background for this study? Response: At a very early stage of COVID 19 pandemic, the scientific community identified that respiratory droplet is the primary mode of transmission of the SARS-CoV2 virus. Naturally, the health agencies have encouraged facemasks to restrict these droplets from spreading during respiratory events, like coughing, sneezing, talking, etc. While WHO recommended using either N95 masks or other types of three-layer masks, due to a sharp increase in demand and scarcity in supplies, a variety of either home-made or locally purchased masks became popular. Naturally, one wonders if these single- and double-layer masks provide enough protection. To provide some insight into this critical question, our team, which also includes Professor Swetaprovo Chaudhuri from the University of Toronto, and Professor Saptarshi Basu of the Indian Institute of Science, experimentally analyzed what happens to the respiratory droplets when they impact single- and multi-layer masks.  (more…)
Author Interviews, Infections, OBGYNE, Pharmaceutical Companies / 21.01.2021

MedicalResearch.com interview with: Dr. Stephen Brand, Chief Development Officer Mycovia Pharmaceuticals  Dr. Stephen Brand discusses the results of Mycovia’s three Phase 3 studies for recurrent vaginal yeast infections (RVVC )and what’s next for the company.  MedicalResearch.com: What is the background for these Phase 3 studies? Answer: Our Phase 3 clinical program for our oral therapy oteseconazole was comprised of three trials enrolling more than 870 patients at 176 sites across 11 different countries. Two of these trials, referred to as VIOLET were identical Phase 3 randomized, double-blind, placebo-controlled clinical trials to evaluate the safety of oteseconazole and its ability to prevent episodes of recurrent vulvovaginal candidiasis (RVVC), commonly referred to as chronic yeast infection. The trials took place over 48 weeks in subjects with an established disease history of at least three episodes of acute VVC in the past 12 months. More than 650 patients randomized at 125 sites across 11 countries. The VIOLET trials consisted of two parts: During the first part of the study which lasted two weeks after patients presented with an active VVC episode, patients were treated with three sequential 150mg doses of fluconazole. The second part consisted of 12 weeks, when the patient either took oteseconazole 150mg or a placebo once weekly (according to a random assignment), and then a 36-week follow-up period. In addition, subjects participating in the VIOLET trials in the U.S. who remained infection-free at their Week 48 visit were offered the opportunity to participate in an extension study and are being monitored for an additional 48 weeks to further define the long-term protection profile of oteseconazole. Eighty-five subjects are enrolled. The third Phase 3 study, called ultraVIOLET, was designed to complement and extend VIOLET as a 50-week randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of oteseconazole. In addition the study compared the effectiveness of oteseconazole compared to fluconazole, the current standard of care, to treat an acute VVC infection in the RVVC population. A total of 220 patients were randomized at 51 sites in the U.S. for the ultraVIOLET trial. The ultraVIOLET trial consisted of two parts: In the first part of the study RVVC subjects presenting with an active infection were randomized to receive either 2 days of dosing with oteseconazole or 3 sequential 150 mg doses of fluconazole (every 72 hours). The second part consisted of 11 weeks, when the patient took either oteseconazole or a placebo weekly (according to the random assignment from the first part of the study), and then a 37-week follow-up period. (more…)
Author Interviews, Infections / 09.12.2020

MedicalResearch.com Interview with: Ed Breitschwerdt, DVM, DACVIM The Melanie S. Steele Distinguished Professorship in Medicine Professor, Internal Medicine NC State College of Veterinary Medicine MedicalResearch.com: What is the background for this study? Response: Bartonella species represent a medically underappreciated group of vector-transmitted bacteria that are increasingly implicated in a spectrum of animal and human diseases. Most recently, our research group has focused on the potential role of these bacteria as a cause or co-factor in patients with neuropsychiatric symptoms. This focus is based upon prior case reports and case series generated by our research group and others. (more…)
Author Interviews, COVID -19 Coronavirus, Infections, JAMA, NYU, Race/Ethnic Diversity / 04.12.2020

MedicalResearch.com Interview with: Gbenga Ogedegbe, MD, MPH Dr. Adolph & Margaret Berger Professor of Population Health Director, Division of Health & Behavior Director Center for Healthful Behavior Change Department of Population Health NYU Langone Health NYU School of Medicine MedicalResearch.com: What is the background for this study? Response: The background for the study is the disproportionately higher rates of COVID-19 hospitalizations and deaths in Blacks and Hispanics compared to Whites in major cities across the country. We asked two questions: 1) are there racial/ethnic differences in COVID-19 outcomes (likelihood of testing positive, hospitalizations, severe illness, and deaths) among patients who receive care at NYU Langone Health? If there are differences, are they explained by comorbidity and neighborhood characteristics (poverty, educational status, employment, housing, proportion of Blacks and Hispanics in communities)? (more…)
Author Interviews, Infections, OBGYNE, Pediatrics / 26.11.2020

MedicalResearch.com Interview with: Jessica Miller PhD Postdoc Fellow Murdoch Childrens Research Institute  MedicalResearch.com: What is the background for this study? Response: Cesarean section (CS) may be a lifesaving intervention for women and babies. However, the global proportion of CS births is rapidly increasing and may not be medically justified. As CS has implications for both mother and child, the increasing rates warrant population-level analyses of potential risks. Many suggested long-term outcomes in CS-born children relate to altered immune development. It is possible that differences in the newborn microbiome by mode of birth contribute to the development of early immune responses which may influence the risk of immune-related outcomes, including infection. CS has been associated with an increased risk for specific infection-related hospitalisations, mainly lower respiratory tract and gastrointestinal infections, but it remains unclear whether CS is associated with increased risk of overall infection-related hospitalisation or only certain infection types, and whether risk differs for emergency versus elective/pre-labour CS. (more…)
Author Interviews, Cleveland Clinic, Infections / 31.10.2020

MedicalResearch.com Interview with: MedicalResearch.com Interview with: Curtis J. Donskey, MD Professor of Medicine Case Western Reserve University Staff Physician, Infectious Diseases Section, Louis Stokes Cleveland VA Medical Center MedicalResearch.com: What is the background for this study? Response: The goal of the study was to obtain a better understanding of how healthcare-associated pathogens are transmitted.  Infection control efforts tend to emphasize hand hygiene and cleaning of high-touch surfaces in patient rooms.  However, there is evidence that portable equipment and floors could be underappreciated sources of transmission. We previously found that a nonpathogenic virus inoculated onto floors in patient rooms spread rapidly to the hands of patients and to surfaces in the room and throughout the ward.  This raised concern that pathogens could spread by the same route. (more…)
Author Interviews, Infections, JAMA / 21.10.2020

MedicalResearch.com Interview with: Liliana Sanchez-Gonzalez MD, MPH Medical Epidemiologist Dengue Branch – Division of Vector Borne Diseases Centers for Disease Control and Prevention San Juan, PR MedicalResearch.com: What is the background for this study? Would you briefly explain the significance of prion disease? Response: Prion diseases are neurodegenerative diseases that occur in animals and humans. These diseases are caused by an infectious agent known as a prion. While the accuracy of diagnostic tests using cerebrospinal fluid or brain imaging from living patients has improved greatly in recent years, analysis of brain tissue is still necessary to confirm the diagnosis of these diseases. Human prion disease cases are rare, but always fatal. There have been around 500 reported cases annually in the US in recent years. A very small percentage of human prion disease cases are acquired, meaning they are caused by an exposure to the infectious agent from an external source. The most well-known acquired human prion disease is variant Creutzfeldt-Jakob disease (vCJD), which was first described in the United Kingdom in 1996 and linked to consumption of contaminated beef from cattle with the animal prion disease bovine spongiform encephalopathy (BSE, or “mad cow” disease). The only US state where classic BSE has been reported is Washington, where an infected dairy cow was imported from Canada in 2003. Beef from the slaughtered cow was processed for human consumption, and beef from cattle slaughtered the same day at the involved slaughter plant was recalled. After this incident, the Washington State Department of Health, in collaboration with the US Centers for Disease Control and Prevention and the National Prion Disease Pathology Surveillance Center (NPDPSC), implemented enhanced human prion disease surveillance. All patients with positive results from tests conducted at the NPDPSC are investigated. We present the results of 12 years of human prion disease surveillance, from 2006 to 2017, plus results of surveillance for vCJD through July 2020. (more…)
Author Interviews, Critical Care - Intensive Care - ICUs, Infections, PLoS / 17.09.2020

MedicalResearch.com Interview with: Prof. Alexandre Mebazaa Head of the Department of Anesthesia and Critical Care Hôpital Lariboisiere and of the Research group MASCOT supported by Inserm and the Université de Paris (Paris, France). Prof. Mebazaa is the principle investigator of the recently published preclinical experiments on Procizumab, a potent, pre-clinical drug candidate targeting DPP3 in patients with acute mycardial depression.  MedicalResearch.com: What is the background for this study? What is the significance of DPP3?  Response: The global burden of sepsis counts for one in three deaths world-wide. Recent findings have shown that circulating Dipeptidyl Pepidase 3 (cDPP3) is elevated in critical patients, including cardiogenic shock and septic patients, with the highest DPP3 blood levels found in non-survivors. Dipeptidyl Peptidase 3 (DPP3) is an intracellular peptidase that is released into the bloodstream upon cell injury and death, where it inactivates many circulating peptides including angiotensin II. This process likely leads to cardiac depression. Procizumab is a humanized monoclonal antibody in preclinical development that targets and modulates DPP3. The aim of the current study was to evaluate the benefits of inhibiting circulating DPP3 by Procizumab in a preclinical model of sepsis-induced myocardial depression. (more…)
Author Interviews, COVID -19 Coronavirus, Hospital Acquired, Infections, JAMA / 10.09.2020

MedicalResearch.com Interview with: Chanu Rhee MD MPH Associate Hospital Epidemiologist Attending Physician, Infectious Diseases and Critical Care Medicine Assistant Professor of Medicine Brigham and Women's Hospital MedicalResearch.com: What is the background for this study?   Response: Many patients have been avoiding essential care during the COVID-19 pandemic due to fear of contracting SARS-CoV-2 in healthcare settings. Little is known, however about the adequacy of infection control practices in preventing nosocomial COVID-19 in U.S. acute care hospitals. We therefore conducted this observational study to determine the incidence of nosocomial COVID-19 in patients hospitalized at a large academic medical center in Boston (Brigham and Women’s Hospital) during the first 12 weeks of the surge in Massachusetts.    (more…)
Author Interviews, Infections, JAMA / 08.09.2020

MedicalResearch.com Interview with: Yaa-Hui Dong PhD Faculty of Pharmacy National Yang-Ming University Taipei, Taiwan MedicalResearch.com: What is the background for this study? Response: Previous observational studies found that fluoroquinolones may be associated with more than 2-fold increased risk of aortic aneurysm or aortic dissection (AA/AD). However, these studies might not well address the influence of concurrent infection, which is also a suggested risk factor for AA. Moreover, most of these studies compared fluoroquinolone use versus no fluoroquinolone use, which might overestimate the risk with fluoroquinolones as patients on fluoroquinolones may have more severe infection versus those not on fluoroquinolones. (more…)
Alzheimer's - Dementia, Author Interviews, Infections / 01.09.2020

MedicalResearch.com Interview with: Hariom Yadav, PhD Assistant Professor, Molecular Medicine Wake Forest School of Medicine  MedicalResearch.com: What is the background for this study? What are the main findings? Response: As gut microbiota is linked with all kind of known human diseases, however, commonly studied microorganisms are bacteria. Our study is first-of-its kind to discover the role of fungi living in our gut to influence our brain health like Alzheimer’s disease pathology in humans. It also describes that a Mediterranean ketogenic diet can beneficially change fungi and bacteria populations to improve brain health.  (more…)
Author Interviews, Infections, Schizophrenia / 05.08.2020

MedicalResearch.com Interview with: GeNeuro Hervé Perron PhD Chief Scientific Officer at GeNeuro MedicalResearch.com: What is the background for this study? Response: Human endogenous retroviruses (HERVs), remnants of ancestral viral genomic insertions, are known to represent 8% of the human genome and are associated with several pathologies. Certain proteins produced by HERVs have previously been found to be involved in pathogenic mechanisms linked to, e.g., multiple sclerosis (MS) or amyotrophic lateral sclerosis.  However, despite previous results having shown an abnormal expression of HERV-W in patients with schizophrenia or bipolar disorder, the mechanisms involved in these psychiatric disorders are poorly understood. (more…)
Author Interviews, Flu - Influenza, Infections, NEJM, Vaccine Studies / 15.07.2020

MedicalResearch.com Interview with: Frederick Hayden MD Stuart S Richardson Professor Emeritus of Clinical Virology Professor Emeritus of Medicine Division of Infectious Diseases and International Health University of Virginia  MedicalResearch.com: What is the background for this study? Response: Although primary prevention approach for influenza infections is vaccination, vaccine efficacy is incomplete and uptake rates are variable in the population. Preventing people who have been exposed to someone with influenza from developing the disease is an important way to prevent its rapid spread, reduce the disruption to peoples' lives and, in some cases, reducing the risk of serious illness or even death.  Prior studies have shown that antivirals like oseltamivir and inhaled zanamivir can reduce the risk influenza illness in those exposed. The BLOCKSTONE study was designed to assess the efficacy of postexposure prophylaxis with a single oral dose of baloxavir for the preventing influenza in household contacts. This antiviral drug was approved first in 2018 for treatment of adults with uncomplicated influenza.  (more…)